Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxidex Ophthalmic Solution for Marginal Corneal Infiltrates
2017-002732-17Phase 2
- Sponsor
- Alcon Inc.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of moxifloxacin + dexamethasone in Corneal infiltrative event (CIE), sponsored by Alcon Inc. Primary endpoint: Resolution of Corneal Stromal Infiltrates.
02
Drugs
moxifloxacin + dexamethasone
03
Conditions
Corneal infiltrative event (CIE)
Beyond the preview
Go deeper on 2017-002732-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002732-17.